Insight

Bishoy Morris Faltas: Excited to Present CLONEVO Trial Results at ASCO 2025 Annual Meeting

Photo of Dr. Bishoy M. Faltas from weill.cornell.edu

May 26, 2025, 14:00

Bishoy Morris Faltas: Excited to Present CLONEVO Trial Results at ASCO 2025 Annual Meeting

Bishoy Morris Faltas, Chief Research Officer at the Englander Institute for Precision Medicine and an Associate Professor of Medicine and Cell and Developmental Biology at Weill Cornell Medicine, shared a post on X:

“Beyond excited to present the results of our investigator-initiated CLONEVO trial at ASCO25! Arie Crown Theater on May 31, 2025

Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in:

– 31% pathologic downstaging

– Clear on-target activity through low Rb phosphorylation and Ki67. Measured by spatial immune mass cytometry in more than 630,000 single cells from matched pre-/post-abemaciclib tissues

– Serial ctDNA analysis shows tumor fraction reduction was driven by abema, not TURBT

– Tumors with CCND1 amplification are more likely to respond (very cool underlying biology!)

– decreased expression of critical DNA damage proteins TOBP1 and RAD51. Providing rationale for testing sequencing CDK4/6 inhibitors after DNA-damaging therapies, including ADCs, to inhibit cancer cells from repairing double-strand DNA breaks.”

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance, shared this post on X, adding:

“Congratulations Bishoy M. Faltas and team for very elegant work!”

Abstract Title: CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment.

Authors: Bishoy M. Faltas, Mohamed Osman, Mark G. Evans, Daniel Margolis, Cora N. Sternberg, Jones T. Nauseef, Ana M. Molina, David M. Nanus, Neal A. Patel, Rohit K. Jain, Juan Miguel Mosquera, Philip Abbosh, Manuel Hidalgo, Nicolas Robine, William F. Hooper, Olivier Elemento, Namrata Peswani, Suzanne Cole, Douglas Scherr, Scott T. Tagawa, Weill Cornell EIPM

Read Full Abstract on ASCO.

CLONEVO Trial

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Insight

OncoDaily

Insight

Bishoy Morris Faltas: Excited to Present CLONEVO Trial Results at ASCO 2025 Annual Meeting

“Beyond excited to present the results of our investigator-initiated CLONEVO trial at ASCO25! Arie Crown Theater on May 31, 2025

Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in:

– 31% pathologic downstaging

– Clear on-target activity through low Rb phosphorylation and Ki67. Measured by spatial immune mass cytometry in more than 630,000 single cells from matched pre-/post-abemaciclib tissues

– Serial ctDNA analysis shows tumor fraction reduction was driven by abema, not TURBT

– Tumors with CCND1 amplification are more likely to respond (very cool underlying biology!)

– decreased expression of critical DNA damage proteins TOBP1 and RAD51. Providing rationale for testing sequencing CDK4/6 inhibitors after DNA-damaging therapies, including ADCs, to inhibit cancer cells from repairing double-strand DNA breaks.”

“Congratulations Bishoy M. Faltas and team for very elegant work!”